FDA Update: Voluntary Recall For Clopidogrel Tablets USP, 75 mg

International Laboratories recently issued a consumer-level voluntary recall for Clopidogrel Tablets, USP 75mg, due to product mislabeling. The product is labeled as Clopidogrel Tablets USP 75mg, but may contain Clopidogrel 75mg or Simvastatin USP 10mg. Affected products include NDC #54458-888-16 and Lot #117099A. Skipped doses of the platelet inhibitor lead to an increased risk of heart attack and stroke, and accidental consumption of Simvastatin may cause other side effects, including fetal harm and myopathy. Patients currently taking Clopidogrel should not stop intake without speaking to their physician.

Clinical Topics: Dyslipidemia, Statins

Keywords: Platelet Aggregation Inhibitors, Simvastatin, Ticlopidine, Myocardial Infarction, Stroke, Risk, Tablets, Muscular Diseases, ACC Advocacy

< Back to Listings